Amarin (NASDAQ:AMRN) recently reported data from a long-running study of its fish oil pill, Vascepa, that could reshape how cardiologists treat their patients.
In today's clip from The Motley Fool's Industry Focus: Healthcare, host Shannon Jones and Motley Fool contributor Todd Campbell discuss how Vascepa can reduce the risk of major cardiovascular events, and why the study's results may turn Vascepa into a billion-dollar blockbuster.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,